CUE, US22978P2056

B. Riley sets USD 83 target for Cue Biopharma stock

Published on 10/20/2026 at 21:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

An insider sold 1,144 shares at USD 28.05 on October 12, 2026. Cue Biopharma stock costs EUR 15.29 on October 20, 2026.

Analyst target and reporting date

B. Riley Financial set a USD 83.00 price target for Cue Biopharma on October 1, 2026.
An insider sold 1,144 shares at USD 28.05 on October 12, 2026.
Cue Biopharma stock costs EUR 15.29 at Lang & Schwarz on October 20, 2026 at 9:31 p.m. CEST.
Third-quarter results are estimated for November 11, 2026.

CUE, US22978P2056, Illustration mit AI erstellt.

B. Riley Financial set a USD 83.00 price target for Cue Biopharma stock on October 1, 2026, while maintaining its Buy rating, according to Investing.com. Cue Biopharma was trading at EUR 15.29 at Lang & Schwarz on October 20, 2026 at 9:31 p.m. CEST.

The target remains far above the quote

The target is denominated in USD, so it cannot be netted directly against the euro quotation. The latest structured market reading put Cue Biopharma at USD 17.18 on October 20, 2026, with a market capitalization of USD 124.8 million and a 52-week range of USD 4.97 to USD 45.50.

The company is a clinical-stage biotechnology business developing immune therapies. Its investor-relations profile identifies CUE-221 as an anti-IgE antibody moving toward a Phase 2b/3 study in chronic spontaneous urticaria and a planned Phase 2 study in food allergy, according to Cue Biopharma.

What does the latest quarter add?

For the second quarter of 2026, Cue Biopharma reported USD 7.88 million in revenue, compared with a USD 3.00 million consensus estimate, while adjusted earnings per share were a USD 24.14 loss against a USD 1.69 loss expectation, according to InsiderTrades. The revenue beat did not prevent a substantial earnings shortfall.

Dates and insider activity

On October 12, 2026, an insider sold 1,144 shares at an average USD 28.05, for proceeds of USD 32,089.20, according to InsiderTrades. MarketBeat estimates the next quarterly results for November 11, 2026, with a revenue consensus of USD 1.03 million and a consensus loss of USD 2.24 per share, according to MarketBeat.

Stock position and peers

Cue Biopharma's USD 124.8 million market value is small beside Celldex Therapeutics at USD 2.4 billion and Immunic at USD 101.3 million. On October 20, 2026, Celldex traded at USD 30.38, up 2.39 percent, while Immunic traded at USD 7.42, up 6.20 percent. These comparisons describe scale and daily positioning rather than a valuation recommendation.

Price and dates matter next

The combination of a USD 83.00 analyst target, a USD 124.8 million market capitalization and the November 11, 2026 reporting date leaves clinical progress and financing needs as the main figures for the next update. The euro quotation remains the relevant German trading reference for this report.

Cue Biopharma was trading at EUR 15.29 at Lang & Schwarz on October 20, 2026 at 9:31 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Cue Biopharma stock.